GSK says long-acting HIV prevention drug 66% more effective than Truvada

GSK says long-acting HIV prevention drug 66% more effective than TruvadaHIV incidence rate - or the number of people who contract the infection in a period - was 0.41% with the injection, compared with 1.22% with Gilead's Truvada, final data from a study presented at the virtual AIDS conference showed. Truvada is currently the standard of care for preventing HIV, but GSK hopes to challenge its dominance by making shorter, long-lasting regimens and less toxic alternatives through its ViiV Healthcare unit. "This advancement has the potential to be a game-changer for HIV prevention, offering ... the convenience of reduced dosing from daily to just six times per year," said Kimberly Smith, head of research and development at ViiV Healthcare.




from Yahoo News - Latest News & Headlines https://ift.tt/2ZK5Fzc
via Latest News

Comments

Post a Comment

Popular posts from this blog

Apple is taking up to $150 off the Beats Studio Pro and Studio Buds Plus - The Verge

Apple is taking up to $150 off the Beats Studio Pro and Studio Buds Plus    The Verge Amazon is having a major sale on Beats Studio Pro wireless headphones with $150 off    NJ.com Beats Headphones and Earbuds See Up to 43% in Savings at Apple and Amazon    CNET Apple Launches Big Discounts on Beats Earphones    MacRumors Apple launches Beats spring sale on latest Studio Pro headphones at $200 and Studio Buds+ at $130    9to5Toys from Technology - Latest - Google News https://ift.tt/3NZjEGc via Technology
Read more